These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 31699318)
1. Why delay in effective treatment for Alzheimer's disease and related conditions. Iqbal K; Liu F; Gong C; Dai C; Hu W Prog Mol Biol Transl Sci; 2019; 168():243-256. PubMed ID: 31699318 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for Alzheimer's disease. Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646 [TBL] [Abstract][Full Text] [Related]
5. Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches. Rüb U; Stratmann K; Heinsen H; Seidel K; Bouzrou M; Korf HW J Alzheimers Dis; 2017; 57(3):683-696. PubMed ID: 28269779 [TBL] [Abstract][Full Text] [Related]
6. Status and future directions of clinical trials in Alzheimer's disease. Plascencia-Villa G; Perry G Int Rev Neurobiol; 2020; 154():3-50. PubMed ID: 32739008 [TBL] [Abstract][Full Text] [Related]
7. Tau immunotherapy for Alzheimer's disease. Pedersen JT; Sigurdsson EM Trends Mol Med; 2015 Jun; 21(6):394-402. PubMed ID: 25846560 [TBL] [Abstract][Full Text] [Related]
8. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. Cribbs DH CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639 [TBL] [Abstract][Full Text] [Related]
9. Tau passive immunization inhibits not only tau but also Aβ pathology. Dai CL; Tung YC; Liu F; Gong CX; Iqbal K Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model. Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551 [TBL] [Abstract][Full Text] [Related]
14. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Boche D; Donald J; Love S; Harris S; Neal JW; Holmes C; Nicoll JA Acta Neuropathol; 2010 Jul; 120(1):13-20. PubMed ID: 20532897 [TBL] [Abstract][Full Text] [Related]
15. Tau immunotherapies for Alzheimer's disease. Hoskin JL; Sabbagh MN; Al-Hasan Y; Decourt B Expert Opin Investig Drugs; 2019 Jun; 28(6):545-554. PubMed ID: 31094578 [TBL] [Abstract][Full Text] [Related]
16. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? Panza F; Logroscino G; Imbimbo BP; Solfrizzi V Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401 [TBL] [Abstract][Full Text] [Related]
17. [Development of antibodies for immunotherapy of Alzheimer's disease]. Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552 [TBL] [Abstract][Full Text] [Related]
18. Active full-length DNA Aβ Rosenberg RN; Fu M; Lambracht-Washington D Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039 [TBL] [Abstract][Full Text] [Related]
20. Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles. Iqbal K; Liu F; Gong CX Biochem Pharmacol; 2014 Apr; 88(4):631-9. PubMed ID: 24418409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]